indiamed
  • News
  • Opinion
  • Interviews
  • IT
  • Finance
  • Strategy
    • Innovation
  • Magazine
  • News
  • Opinion
  • Interviews
  • IT
  • Finance
  • Strategy
    • Innovation
  • Magazine
facebook x icon x icon linkedin linkedin
all-news

Wellthy Therapeutics announces US expansion

IMT News Desk
Completes FDA CFR Part 11, FDA CFR Part 820, and HIPAA Certification for its platform Wellthy Therapeutics, a global leader in digital health and digital therapeutics, has completed its FDA 21 CFR Part 820, FDA 21 CFR Part 11, and HIPAA certification for its disease-agnostic, modular, software-as-a-medical-device (SaMD) platform. These international registrations further solidify the company's commitment to maintaining the highest standards of data security, data privacy, quality and regulatory compliance in the development and manufacturing of digital health solutions for customers in the US and worldwide, and reinforce its leadership in the SaMD space. In addition to these recent certifications, the Wellthy Therapeutics platform is already compliant with EU MDR Class 1, ISO 13485, ISO 27001, ISO 27701, IEC 62304, and GDPR, demonstrating its dedication to delivering cutting-edge digital health solutions that consistently meet global regulatory requirements. The platform simplifies the ability of pharma, HUBs, providers, and health plans to launch and scale globally compliant digital health and SaMD solutions. Clients leverage the platform to configure and commercialise their customized digital health and SaMD solutions that are deployable in a matter of weeks and at a fraction of traditional costs while addressing their specific business goals and complex patient needs. Over 150,000 patients have benefitted from Wellthy Therapeutics' platform so far, highlighting the value that the company's platform brings, and its continued leadership in the clinical outcomes and patient engagement space. Abhishek Shah, CEO, Wellthy Therapeutics, commented, "Our recent US certifications, along with our existing compliance with other international standards, reinforce our mission to revolutionize digital health worldwide. Our modular SaMD platform has enabled medication and health brands to improve patient identification and onboarding, substantially differentiate products, increase adherence and reduce the overall cost of care and medical claims; all while improving patient quality of life and solving unmet patient needs. In doing so, we are pushing the boundaries of medicine and creating a brighter future for patients around the world."

Recommended

Precision Oncology Goes Local: 4baseCare’s Genomics Lab and Atlas Set to Transform Cancer Care

India solidifies position as most attractive global CDMO destination: LoEstro Report

IKS Health achieves HITRUST r2 recertification

Wockhardt Hospitals launches My Patient, My Idea initiative for nurses

Granules India extends CSR activity for TB patients

Dr Vinay Munikoty Venkatesh joins SIOP as South India’s Country Ambassador

Biocon to Invest $200 Million This Year in Growth and Expansion

Young Lifters, Old Hips: Steroids and Powder Use Fuel Hip Damage in 20s

Indiamedtoday

A premier media platform empowering healthcare professionals with critical business insights, news, and innovations to excel in a rapidly evolving industry.

EMAIL editorial@indiamedtoday.com

EMAIL sales@indiamedtoday.com

quick links

news health it interview opinion strategy magazine privacy policy terms and conditions

subscribe to our newsletter

Stay updated with the latest breakthroughs in Indian healthcare, medical research, and wellness insights.

    follow us

    facebook x icon x icon linkedin linkedin
    Copyright © 2025 INDIAMED TODAY Marketed By Screetract Solutions